ALSO NOTED: At GSK, a public race for the top spot; Encysive plans another Phase III;Elixir announces $86M IPO; and much more..

> GlaxoSmithKline is holding a very public race to choose the company's next CEO. GSK's current chief, Jean-Pierre Garnier, announced in September 2005 that he was retiring and that the company would be considering internal candidates for the job. Report

> Encysive Pharmaceuticals says it will forge ahead with another Phase III trial of Thelin, which has earned three approvable letters from the FDA but no approval. Report

> Dyadic has fired its CEO, Mark Emalfarb, following an accounting scandal. Release

> Elixir Pharmaceuticals has filed for an $86 million IPO. Elixir was a 2003 Fierce 15 company. Release

> Nanogen says it will lay off 13 people from its microarray sector. Report

> As the ink was still drying on the new drug-safety bill, FDA shuffled its management, bringing back Janet Woodcock as director of the Center for Drug Evaluation and Research. Report

> Looks like pharma and the FDA need some damage control in the public opinion department. Americans don't trust drugs bearing a "Made in China" or "Made in India" label, according to a new study conducted by American University, and they blame drug companies for the rising cost of meds. Report

And Finally... Aromatherapy massages radically reduced the stress level of ER nurses. Report

Suggested Articles

Solid Bio fixed the manufacturing issue that led to a partial clinical hold on its DMD trial, but a full hold remains.

Commissioner Scott Gottlieb has laid out the reasons why he thinks the FDA needs a double-digit budget bump.

GW's cannabis-based epilepsy drug scored a favorable review from FDA staff ahead of an expert panel meeting.